INT36674

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1984
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 11
Total Number 11
Disease Relevance 2.71
Pain Relevance 4.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Phc1) DNA binding (Phc1)
Anatomy Link Frequency
plasma 1
stellate ganglion 1
sympathetic ganglion 1
ganglion 1
neural 1
Phc1 (Mus musculus)
Pain Link Frequency Relevance Heat
Clonidine 50 99.98 Very High Very High Very High
Locus ceruleus 12 99.36 Very High Very High Very High
anesthesia 4 98.78 Very High Very High Very High
Dopamine 99 96.64 Very High Very High Very High
depression 10 91.40 High High
tetrodotoxin 1 89.56 High High
Spinal cord 8 89.48 High High
antagonist 3 84.56 Quite High
Action potential 2 79.48 Quite High
behavioral therapy 4 70.36 Quite High
Disease Link Frequency Relevance Heat
Ganglion Cysts 12 99.70 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 226 96.48 Very High Very High Very High
Depression 10 91.40 High High
Syndrome 2 89.12 High High
Hypersensitivity 2 84.48 Quite High
Substance Abuse 17 82.56 Quite High
Affective Disorder 3 81.12 Quite High
Tics 2 76.84 Quite High
Headache 2 46.76 Quite Low
Sleep Disorders 8 46.24 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Administration of clonidine (0.3-3.0 micrograms i.a.) directly to the stellate ganglion did not significantly decrease the amplitude of responses evoked by submaximal hypothalamic stimulation but did inhibit hypothalamic-evoked EDR when administered intrathecally at the C6 to T2 spinal levels.
Negative_regulation (inhibit) of EDR in stellate ganglion associated with ganglion cysts and clonidine
1) Confidence 0.37 Published 1988 Journal Eur. J. Pharmacol. Section Abstract Doc Link 3384003 Disease Relevance 0.25 Pain Relevance 0.61
Experiments were designed to determine the neural site of action for clonidine inhibition of sympathetic-cholinergic electrodermal responses (EDR) in anesthetized cats.
Negative_regulation (inhibition) of EDR in neural associated with clonidine
2) Confidence 0.37 Published 1988 Journal Eur. J. Pharmacol. Section Abstract Doc Link 3384003 Disease Relevance 0.16 Pain Relevance 0.44
Administration of clonidine to the ganglion, however, did depress EDR evoked by the ganglionic stimulant, 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP, 10 micrograms i.a.).
Negative_regulation (depress) of EDR in ganglion associated with ganglion cysts and clonidine
3) Confidence 0.37 Published 1988 Journal Eur. J. Pharmacol. Section Abstract Doc Link 3384003 Disease Relevance 0.26 Pain Relevance 0.66
Although a possible DMPP-clonidine interaction appears to take place at the level of the sympathetic ganglion, it is unlikely that ganglionic blockade contributes significantly to clonidine inhibition of EDR evoked by electrical activation of the nervous system.
Negative_regulation (inhibition) of EDR in sympathetic ganglion associated with ganglion cysts and clonidine
4) Confidence 0.37 Published 1988 Journal Eur. J. Pharmacol. Section Abstract Doc Link 3384003 Disease Relevance 0.30 Pain Relevance 0.75
Atropine (200 micrograms/kg) depressed the EDR elicited by both peripheral and central stimulation whereas hexamethonium (20 mg/kg) only inhibited the central EDR.
Negative_regulation (inhibited) of EDR
5) Confidence 0.37 Published 1984 Journal Eur. J. Pharmacol. Section Abstract Doc Link 6143676 Disease Relevance 0 Pain Relevance 0.10
Pentobarbital anesthesia and cold storage of the preparations for 24 h significantly decreased the EDR without effecting the contractile response of the rings.
Negative_regulation (decreased) of EDR associated with anesthesia
6) Confidence 0.19 Published 2001 Journal Endothelium Section Abstract Doc Link 11824475 Disease Relevance 0 Pain Relevance 0.25
To the best of our knowledge, this is the first study to demonstrate MPH’s activity-reducing action in healthy participants.
Negative_regulation (reducing) of MPH
7) Confidence 0.08 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2701285 Disease Relevance 0 Pain Relevance 0.16
Methylphenidate hydrochloride (MPH) is a piperidine derivative, structurally related to amphetamines.
Negative_regulation (derivative) of MPH
8) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 0.90 Pain Relevance 0.27
The I(MPH) was blocked by Co(2+) (1 mM).
Negative_regulation (blocked) of MPH
9) Confidence 0.03 Published 2002 Journal J. Neurophysiol. Section Abstract Doc Link 11877494 Disease Relevance 0.29 Pain Relevance 0.62
Before MPH treatment, the plasma growth hormone (GH) rose to 31.3 +/- 4.6 (Mean +/- SE) ng/ml; during MPH treatment, the GH peak was only 14.8 +/- 3.2 ng/ml; one day after discontinuation of MPH, GH rose to only 20.8 +/- 3.9 ng/ml.
Negative_regulation (discontinuation) of MPH in plasma
10) Confidence 0.03 Published 1984 Journal Life Sci. Section Abstract Doc Link 6482679 Disease Relevance 0.41 Pain Relevance 0.35
Our finding to suggest that RT variability may be predictive of MPH treatment response provides clinicians with a possible clinical indicator to be used in treatment planning with MPH.



Negative_regulation (predictive) of MPH
11) Confidence 0.02 Published 2009 Journal Yonsei Medical Journal Section Body Doc Link PMC2768239 Disease Relevance 0.15 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox